Patient & Survivor Care
Daily News Podcast
Daily News Special: SABCS
The latest clinical medicine news from the 2018 annual San Antonio Breast Cancer Symposium.
From the Journals
Poor-prognosis cancers linked to highest suicide risk in first year
Pancreatic and lung cancer patients had high rates of suicide in comparison to the general population, while breast and prostate cancer patients...
From the Journals
Higher AML, MDS risk linked to solid tumor chemotherapy
Most tMDS/AML cases expected to occur within the next 5 years will be attributable to chemotherapy, the researchers reported.
Hard Questions
Should doctors disclose preliminary results?
False alarms are terrifying, and false reassurance is cruel, yet all the while, excessive waiting can feel excruciating.
Conference Coverage
Lack of gut diversity hurts survival after HCT
SAN DIEGO – Patients with low diversity of intestinal microflora have worse overall survival after hematopoietic cell transplant.
From the Journals
Survivors of childhood Hodgkin lymphoma face 14-fold risk of second cancers
The findings highlight the need to screen high-risk subgroups of cancer survivors.
Conference Coverage
Hematologists are outliers in care at the end of life
SAN DIEGO – Dr. David Hui, of MD Anderson Cancer Center, is calling for an attitude shift around palliative care.
Conference Coverage
QOL is poorer for young women after mastectomy than BCS
SAN ANTONIO – A cohort study of 560 breast cancer survivors aged 40 or younger at diagnosis finds that breast satisfaction and several domains of...
Conference Coverage
Data underscore the importance of lifestyle interventions in breast cancer patients
SAN ANTONIO – Data support lifestyle interventions in women with breast cancer; jury is still out on the effects of interventions on disease...
Conference Coverage
Oxybutynin rapidly quells hot flashes
SAN ANTONIO - Oxybutynin reduced hot flash scores by at least two-thirds, improved measures of quality of life, and was safe and well tolerated in...
Conference Coverage
Phase 3 data support apixaban for cancer-associated VTE
The rate of major bleeding was similar with apixaban and dalteparin.